Oral low-dose dexamethasone for androgen-independent prostate cancer patients

Oncology Letters

Volumn 1, Issue 1, 2010, Pages 73-79

  Komiya, Akira ^a,b   Shimbo, Masaki ^a,c   Suzuki, Hiroyoshi ^a   Imamoto, Takashi ^a   Kato, Tomonori ^a   Fukasawa, Satoshi ^a   Kamiya, Naoto ^a   Naya, Yukio ^a   Mori, Ikuo ^c   Ichikawa, Tomohiko ^a  

^a CHIBA UNIVERSITY HOSPITAL   (Japan)

^b UNIVERSITY OF TOYAMA   (Japan)

^c Imperial Foundation Saiseikai Utsunomiya Hospital   (Japan)

Author keywords

Androgen; Dexamethasone; Prostate cancer

Indexed keywords

ANALGESIC AGENT; ANTIANDROGEN; DEXAMETHASONE; ESTRAMUSTINE; ETOPOSIDE; GONADORELIN AGONIST; HEMOGLOBIN; HYDROCORTISONE; INTERLEUKIN 6; NONSTEROID ANTIINFLAMMATORY AGENT; PREDNISOLONE; PREDNISONE; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ANDROGEN DEPRIVATION THERAPY; ANDROGEN INDEPENDENT PROSTATE CANCER; ARTICLE; BONE METASTASIS; BONE PAIN; CANCER PATIENT; CASTRATION; CATARACT; COHORT ANALYSIS; CONTROLLED STUDY; CORTICOSTEROID INDUCED MYOPATHY; DEPRESSION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG WITHDRAWAL; ECCHYMOSIS; EDEMA; FOLLOW UP; FRACTURE; HEMOGLOBIN BLOOD LEVEL; HISTOPATHOLOGY; HOT FLUSH; HUMAN; HYPERTENSION; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MOON FACE; OSTEOPOROSIS; PROGRESSION FREE SURVIVAL; PROSTATE CANCER; RETROSPECTIVE STUDY; SIDE EFFECT; STOMACH ULCER; TREATMENT DURATION; TREATMENT RESPONSE; WEIGHT GAIN;

EID: 77955765851     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol_00000013     Document Type: Article

References (28)

1. Scher HI, Steineck G and Kelly WK: Hormone-refractory (D3) prostate cancer: refining the concept. Urology 46: 142-148, 1995.
2. Fakih M, Johnson CS and Trump DL: Glucocorticoids and treatment of prostate cancer: a preclinical and clinical review. Urology 60: 553-561, 2002.
3. Nishimura K, Nonomura N, Yasunaga Y, et al: Low doses of oral dexamethasone for hormone-refractory prostate carcinoma. Cancer 89: 2570-2576, 2000.
4. Zhang C, Mattern J, Haferkamp A, et al: Corticosteroid-induced chemotherapy resistance in urological cancers. Cancer Biol Ther 5: 59-64, 2006.
5. Weitzman AL, Shelton G, Zuech N, et al: Dexamethasone does not significantly contribute to the response rate of docetaxel and estramustine in androgen-independent prostate cancer. J Urol 163: 834-837, 2000.
6. Chang CY, Walther PJ and McDonnell DP: Glucocorticoids manifest androgenic activity in a cell line derived from a metastatic prostate cancer. Cancer Res 61: 8712-8717, 2001.
7. Reyes-Moreno C, Frenette G, Boulanger J, Lavergne E, Govindan MV and Koutsilieris M: Mediation of glucocorticoid receptor function by transforming growth factor beta I expression in human PC-3 prostate cancer cells. Prostate 26: 260-269, 1995.
8. Gao QZ, Lu JJ, Liu ZD, Zhang H, Wang SM and Xu H: Dexamethasone suppresses DU145 cell proliferation and cell cycle through inhibition of the extracellular signal-regulated kinase 1/2 pathway and cyclin D1 expression. Asian J Androl 10: 635-641, 2008.
9. Akakura K, Akimoto S, Ohki T and Shimazaki J: Antiandrogen withdrawal syndrome in prostate cancer after treatment with steroidal antiandrogen chlormadinone acetate. Urology 45: 700-705, 1995.
10. Soloway MS, Hardeman SW, Hickey D, et al: Stratification of patients with metastatic prostate cancer based on extent of disease on initial bone scan. Cancer 61: 195-202, 1988.
11. Lam JS, Leppert JT, Vemulapalli SN, Shvarts O and Belldegrun AS: Secondary hormonal therapy for advanced prostate cancer. J Urol 175: 27-34, 2006.
12. Saad F, Gleason DM, Murray R, et al: Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst 96: 879-882, 2004.
13. Akakura K, Suzuki H, Ueda T, et al: Possible mechanism of dexamethasone therapy for prostate cancer: suppression of circulating level of interleukin-6. Prostate 56: 106-109, 2003.
14. Okamoto M, Lee C and Oyasu R: Interleukin-6 as a paracrine and autocrine growth factor in human prostatic carcinoma cells in vitro. Cancer Res 57: 141-146, 1997.
15. Chung TD, Yu JJ, Spiotto MT, Bartkowski M and Simons JW: Characterization of the role of IL-6 in the progression of prostate cancer. Prostate 38: 199-207, 1999.
16. Lou W, Ni Z, Dyer K, Tweardy DJ and Gao AC: Interleukin-6 induces prostate cancer cell growth accompanied by activation of stat3 signaling pathway. Prostate 42: 239-242, 2000.
17. Hobisch A, Eder IE, Putz T, et al: Interleukin-6 regulates prostate-specific protein expression in prostate carcinoma cells by activation of the androgen receptor. Cancer Res 58: 4640-4645, 1998.
18. Chen T, Wang LH and Farrar WL: Interleukin 6 activates androgen receptor-mediated gene expression through a signal transducer and activator of transcription 3-dependent pathway in LNCaP prostate cancer cells. Cancer Res 60: 2132-2135, 2000.
19. Ueda T, Bruchovsky N and Sadar MD: Activation of the androgen receptor N-terminal domain by interleukin-6 via MAPKand STAT3 signal transduction pathways. J Biol Chem 277: 7076-7085, 2002.
20. Tannock IF, de Wit R, Berry WR, et al: Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351: 1502-1512, 2004.
21. Petrylak DP, Tangen CM, Hussain MH, et al: Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 351: 1513-1520, 2004.
22. Shimojo M, Hiroi N, Yakushiji F, Ueshiba H, Yamaguchi N and Miyachi Y: Differences in down-regulation of glucocorticoid receptor mRNA by cortisol, prednisolone and dexamethasone in HeLa cells. Endocr J 42: 629-636, 1995.
23. Kelly WK, Curley T, Leibretz C, Dnistrian A, Schwartz M and Scher HI: Prospective evaluation of hydrocortisone and suramin in patients with androgen-independent prostate cancer. J Clin Oncol 13: 2208-2213, 1995.
24. Kantoff PW, Halabi S, Conaway M, et al: Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the cancer and leukemia group B 9182 study. J Clin Oncol 17: 2506-2513, 1999.
25. Tannock I, Gospodarowicz M, Meakin W, Panzarella T, Stewart L and Rider W: Treatment of metastatic prostatic cancer with low-dose prednisone: evaluation of pain and quality of life as pragmatic indices of response. J Clin Oncol 7: 590-597, 1989.
26. Sartor O, Weinberger M, Moore A, Li A and Figg WD: Effect of prednisone on prostate-specific antigen in patients with hormone-refractory prostate cancer. Urology 52: 252-256, 1998.
27. Fuse H, Nozaki T, Fujiuchi Y, Mizuno I, Nagakawa O and Okumura A: Treatment with prednisolone of hormone-refractory prostate cancer. Arch Androl 52: 35-38, 2006.
28. Nishiyama T and Terunuma M: Hormone/antihormone withdrawal and dexamethasone for hormone-refractory prostate cancer. Int J Urol 5: 44-47, 1998.